A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTRA-1
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics
    • 21 May 2013 Tolerability results from a pooled analysis presented at the Digestive Disease Week 2013.
    • 22 Oct 2012 Results from an analysis, that included data from this trial, have been presented at the ACG and UEGW 2012 annual meetings according to an Abbott media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top